Celecoxib enhances radiosensitivity of hypoxic glioblastoma cells through endoplasmic reticulum stress

Neuro-Oncology

Volumn 15, Issue 9, 2013, Pages 1186-1199

  Suzuki, Kenshi ^a   Gerelchuluun, Ariungerel ^a   Hong, Zhengshan ^a   Sun, Lue ^a   Zenkoh, Junko ^b   Moritake, Takashi ^b   Tsuboi, Koji ^b  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

autophagy; celecoxib; ER stress; glioblastoma; hypoxia; radiosensitivity

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2;

ANIMAL CELL; APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CYCLE M PHASE; CELL GROWTH; CELL HYPOXIA; CELL SURVIVAL; CONTROLLED STUDY; ENDOPLASMIC RETICULUM STRESS; ENZYME INHIBITION; G1 PHASE CELL CYCLE CHECKPOINT; G2 PHASE CELL CYCLE CHECKPOINT; GAMMA IRRADIATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIVITY;

AUTOPHAGY; CELECOXIB; ER STRESS; GLIOBLASTOMA; HYPOXIA; RADIOSENSITIVITY;

ANIMALS; CELL HYPOXIA; CELL LINE, TUMOR; CELL SURVIVAL; ENDOPLASMIC RETICULUM STRESS; GAMMA RAYS; GLIOBLASTOMA; HUMANS; MICE; PYRAZOLES; RADIATION TOLERANCE; RADIATION-SENSITIZING AGENTS; SULFONAMIDES;

EID: 84883183250     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/not062     Document Type: Article

References (63)

1. Kleihues P, Ohgaki H. Primaryandsecondaryglioblastomas:fromconcept to clinical diagnosis. Neuro-Oncology. 1999;1(1):44-51.
2. Stupp R, Mason WP, van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England Journal of Medicine. 2005;352(10):987-996. (Pubitemid 40349501)
3. Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New England Journal of Medicine. 2005;352(10):997-1003. (Pubitemid 40349502)
4. Parsons DW, Jones S, Zhang X, et al. An integrated genomic analysis of human glioblastoma multiforme. Science. 2008;321(5897):1807-1812.
5. Lo HW, Cao X, Zhu H, Ali-Osman F. Cyclooxygenase-2 is a novel transcriptional target of the nuclear EGFR-STAT3 and EGFRvIII-STAT3 signaling axes. Molecular Cancer Research: MCR. 2010;8(2):232-245.
6. Paoletti P, Chiabrando C, Gaetani P, et al. Prostaglandins in human brain tumors. Journal of Neurosurgical Sciences. 1989;33(1):65-69. (Pubitemid 19153231)
7. Shi S, Klotz U. Clinical use and pharmacological properties of selective COX-2 inhibitors. European Journal of Clinical Pharmacology. 2008;64(3):233-252.
8. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. The New England Journal of Medicine. 2000;342(26):1946-1952. (Pubitemid 30419089)
9. Kaneko M, Kaneko S, Suzuki K. Prolonged low-dose administrationof the cyclooxygenase-2 inhibitor celecoxib enhances the antitumor activity of irinotecan against neuroblastoma xenografts. Cancer Science. 2009;100(11):2193-2201.
10. Kaneko S, Kaneko M, Fukushima T. Enhanced antitumor effect of lower-dose and longer-term CPT-11 treatment in combination with low-dose celecoxib against neuroblastomaxenografts. International journalofclin-ical oncology/Japan Society of Clinical Oncology. 2013;18(1):116-125.
11. Kardosh A, Golden EB, Pyrko P, et al. Aggravated endoplasmic reticulum stress as a basis for enhanced glioblastoma cell killing by bortezomib in combination with celecoxib or its non-coxib analogue, 2, 5-dimethyl-cel-ecoxib. Cancer Research. 2008;68(3):843-851. (Pubitemid 351206762)
12. Chuang HC, Kardosh A, Gaffney KJ, Petasis NA, Schonthal AH. COX-2 inhibition is neither necessary nor sufficient for celecoxib to suppress tumor cell proliferation and focus formation in vitro. Molecular Cancer. 2008;7:38.
13. Healy SJ, Gorman AM, Mousavi-Shafaei P, Gupta S, Samali A. Targeting the endoplasmic reticulum-stress response as an anticancer strategy. European Journal of Pharmacology. 2009;625(1-3):234-246.
14. Verfaillie T, Garg AD, Agostinis P. Targeting ER stress induced apoptosis and inflammation in cancer. [published online ahead of print August 23, 2010]. Cancer Letters. 2010. doi:10.1016/j.canlet.2010.07.016.
15. Lee AS. GRP78 induction in cancer: therapeutic and prognostic implications. Cancer Research. 2007;67(8):3496-3499. (Pubitemid 46762126)
16. Oyadomari S, Mori M. Roles of CHOP/GADD153 in endoplasmic reticu-lum stress. Cell Death and Differentiation. 2004;11(4):381-389. (Pubitemid 38489416)
17. Gilbert MR, Gonzalez J, Hunter K, et al. A phase I factorial design study of dose-dense temozolomide alone and in combination with thalidomide, iso-tretinoin, and/or celecoxib as postchemoradiation adjuvant therapy for newly diagnosed glioblastoma. Neuro-Oncology. 2010;12(11):1167-1172.
18. Kesari S, Schiff D, Henson JW, et al. Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. Neuro-Oncology. 2008;10(3):300-308.
19. Bertagnolli MM, Eagle CJ, Zauber AG, et al. Celecoxib for the prevention of sporadic colorectal adenomas. The New England Journal of Medicine. 2006;355(9):873-884. (Pubitemid 44315980)
20. Brown JM. The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Research. 1999;59(23):5863-5870. (Pubitemid 30004940)
21. Schroder M, Kaufman RJ. The mammalian unfolded protein response. Annual Review of Biochemistry. 2005;74:739-789. (Pubitemid 40995523)
22. Fels DR, Ye J, Segan AT, et al. Preferential cytotoxicity of bortezomib toward hypoxic tumor cells via overactivation of endoplasmic reticulum stress pathways. Cancer Research. 2008;68(22):9323-9330.
23. Eshleman JS, Carlson BL, Mladek AC, Kastner BD, Shide KL, Sarkaria JN. Inhibition of the mammalian target of rapamycin sensitizes U87 xeno-grafts to fractionated radiation therapy. Cancer Research. 2002;62(24): 7291-7297. (Pubitemid 36025252)
24. Petersen C, Petersen S, Milas L, Lang FF, Tofilon PJ. Enhancementofintrin-sic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clinical Cancer Research: An Official Journal of The American Association for Cancer Research. 2000;6(6):2513-2520. (Pubitemid 30399223)
25. Newcomb EW, Demaria S, Lukyanov Y, et al. The combinationofionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2006;12(15):4730-4737. (Pubitemid 44297827)
26. Van Meir EG, Kikuchi T, Tada M, et al. Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Research. 1994;54(3):649-652. (Pubitemid 24068319)
27. Zhang Z, Wang H, Prasad G, et al. Radiosensitization by antisense anti-MDM2 mixed-backbone oligonucleotide in in vitro and in vivo human cancer models. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research. 2004;10(4):1263-1273. (Pubitemid 38365216)
28. Blaszczyk-Thurin M, Ertl IO, Ertl HC. An experimental vaccine expressing wild-type p53 induces protective immunity against glioblastoma cells with high levels of endogenous p53. Scandinavian Journal of Immunology. 2002;56(4):361-375.
29. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nature Protocols. 2006;1(5):2315-2319.
30. Kanzawa T, Bedwell J, Kondo Y, Kondo S, Germano IM. Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide. Journal of Neurosurgery. 2003;99(6):1047-1052. (Pubitemid 44717401)
31. Jensen RL. Hypoxia in the tumorigenesis of gliomas and as a potential target for therapeutic measures. Neurosurgical Focus. 2006;20(4):E24.
32. Sondergaard KL, Hilton DA, Penney M, Ollerenshaw M, Demaine AG. Expression of hypoxia-inducible factor 1alpha in tumours of patients with glioblastoma. Neuropathology and Applied Neurobiology. 2002;28(3):210-217. (Pubitemid 34639443)
33. Rich JN. Cancer stem cells in radiation resistance. Cancer Research. 2007;67(19):8980-8984. (Pubitemid 47535877)
34. Herschman HR. Primary response genes induced by growth factors and tumor promoters. Annual Review of Biochemistry. 1991;60:281-319.
35. Williams CS, Mann M, DuBois RN. The role of cyclooxygenasesininflam- mation, cancer, anddevelopment. Oncogene. 1999;18(55):7908-7916.
36. Taketo MM. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). Journal of the National Cancer Institute. 1998;90(20):1529-1536. (Pubitemid 28535717)
37. Shono T, Tofilon PJ, Bruner JM, Owolabi O, Lang FF. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Research. 2001;61(11):4375-4381. (Pubitemid 32685762)
38. Lee JJ, Natsuizaka M, Ohashi S, et al. Hypoxia activates the cyclooxygenase-2-prostaglandin E synthase axis. Carcinogenesis. 2010;31(3):427-434.
39. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Research. 2000;60(5):1306- 1311. (Pubitemid 30151999)
40. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Research. 2002;62(3):625-631. (Pubitemid 34126930)
41. Kulp SK, Yang YT, Hung CC, et al. 3-phosphoinositide-dependentprotein kinase-1/Akt signaling represents a major cyclooxygenase-2-indepen-dent target for celecoxib in prostate cancer cells. Cancer Research. 2004;64(4):1444-1451. (Pubitemid 38235615)
42. Du H, Li W, Wang Y, et al. Celecoxib induces cell apoptosis coupled with up-regulation of the expression of VEGF by a mechanism involving ER stress in human colorectal cancer cells. Oncology Reports. 2011;26(2):495-502.
43. Tsutsumi S, Gotoh T, Tomisato W, et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. Cell Death and Differentiation. 2004;11(9):1009-1016. (Pubitemid 39232360)
44. Berridge MJ. The endoplasmic reticulum: a multifunctional signaling organelle. Cell Calcium. 2002;32(5-6):235-249. (Pubitemid 36175747)
45. Hoyer-Hansen M, Jaattela M. Connecting endoplasmicreticulum stressto autophagy by unfolded protein response and calcium. Cell Death and Differentiation. 2007;14(9):1576-1582. (Pubitemid 47278843)
46. Zhang B, Wang Y, Pang X, Su Y, Ai G, Wang T. ERstress inducedbyionising radiation in IEC-6 cells. International Journal of Radiation Biology. 2010;86(6):429-435.
47. He L, Kim SO, Kwon O, et al. ATM blocks tunicamycin-induced endoplas-mic reticulum stress. FEBS Letters. 2009;583(5):903-908.
48. Pyrko P, Kardosh A, Liu YT, et al. Calcium-activated endoplasmic reticulum stress as a major component of tumor cell death induced by 2, 5-dimethyl-celecoxib, a non-coxib analogue of celecoxib. Molecular Cancer Therapeutics. 2007;6(4):1262-1275. (Pubitemid 46711989)
49. Johnson AJ, Hsu AL, Lin HP, Song X, Chen CS. The cyclo-oxygenase-2 inhibitor celecoxib perturbs intracellular calcium by inhibiting endoplasmic reticulum Ca2+-ATPases: a plausible link with its anti-tumour effect and cardiovascular risks. The Biochemical Journal. 2002;366(Pt 3): 831-837.
50. Tanaka K, Tomisato W, Hoshino T, et al. Involvement of intracellular Ca2+ levels in nonsteroidal anti-inflammatory drug-induced apoptosis. The Journal of Biological Chemistry. 2005;280(35): 31059-31067. (Pubitemid 41291840)
51. Penning TD, Talley JJ, Bertenshaw SR, et al. Synthesis and biological evaluation of the 1, 5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] benze nesulfonamide (SC-58635, celecoxib). Journal of Medicinal Chemistry. 1997;40(9):1347-1365. (Pubitemid 27198082)
52. Moretti L, Cha YI, Niermann KJ, Lu B. Switch between apoptosis and autophagy: radiation-induced endoplasmic reticulum stress? Cell Cycle. 2007;6(7):793-798. (Pubitemid 46572616)
53. Mazure NM, Pouyssegur J. Hypoxia-induced autophagy: cell death or cell survival? Current Opinion in Cell Biology. 2010;22(2): 177-180.
54. Feng Z, Zhang H, Levine AJ, Jin S. The coordinate regulation of the p53 and mTOR pathways in cells. Proceedings of the National Academy of Sciences of the United States of America. 2005;102(23): 8204-8209. (Pubitemid 40800067)
55. Crighton D, Wilkinson S, O'Prey J, et al. DRAM, a p53-induced modulator of autophagy, is critical for apoptosis. Cell. 2006;126(1): 121-134. (Pubitemid 44040988)
56. Chiu HW, Ho SY, Guo HR, Wang YJ. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy. 2009;5(4): 472-483.
57. Emdad L, Qadeer ZA, Bederson LB, Kothari HP, Uzzaman M, Germano IM. Is there a common upstream link for autophagic and apoptotic cell death in human high-grade gliomas? Neuro-Oncology. 2011;13(7): 725-735.
58. Kang KB, Zhu C, Yong SK, Gao Q, Wong MC. Enhanced sensitivityof cel-ecoxibin human glioblastoma cells: Induction ofDNA damage leading to p53-dependent G1 cell cycle arrest and autophagy. Molecular Cancer. 2009;8:66.
59. Grosch S, Tegeder I, Niederberger E, Brautigam L, Geisslinger G. COX-2 independent induction of cell cycle arrest and apoptosis in colon cancer cells by the selective COX-2 inhibitor celecoxib. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology. 2001;15(14):2742-2744.
60. Chen M, Gutierrez GJ, Ronai ZA. Ubiquitin-recognition protein Ufd1 couples the endoplasmic reticulum (ER) stress response to cell cycle control. Proceedings of the National Academy of Sciences of the United States of America. 2011;108(22):9119-9124.
61. McAdam BF, Catella-Lawson F, Mardini IA, Kapoor S, Lawson JA, FitzGerald GA. Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proceedings of the National Academy of Sciences of the United States of America. 1999;96(1):272-277. (Pubitemid 29036089)
62. Chen KH, Hsu CC, Song WS, et al. Celecoxib enhances radiosensitivity in medulloblastoma-derived CD133-positive cells. Child's Nervous System: ChNS: Official Journal of the International Society for Pediatric Neurosurgery. 2010;26(11): 1605-1612.
63. Ma HI, Chiou SH, Hueng DY, et al. Celecoxib and radioresistant glioblas-toma-derived CD133+ cells: improvement in radiotherapeutic effects. Laboratory investigation. Journal of Neurosurgery. 2011;114(3): 651-662.